Evidence map›Paper›PMID 24049167›Full record

ArticleJournal of virology2013

An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Benjamin Trinité, Eric C Ohlson, Igor Voznesensky, Shashank P Rana, Chi N Chan, Saurabh Mahajan, Jason Alster, Sean A Burke, Dominik Wodarz, David N Levy

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. A CCR5BMC research notes · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Benjamin TrinitéDepartment of Basic Science, New York University College of Dentistry, New York, New York, USA.
Eric C Ohlson
Igor Voznesensky
Shashank P Rana
Chi N Chan
Saurabh Mahajan
Jason Alster
Sean A Burke
Dominik Wodarz
David N Levy
New York University · USUniversity of California, Irvine · US

Funding

HIV-1 Replication Without IntegrationR01AI078783 · NIAID · NEW YORK UNIVERSITY · PI LEVY, DAVID N · 2009 to 2013
$2.1M
Viruis Dynamics and Multiple Infection of Cells: Computational and Experimental AR01AI093998 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI LEVY, DAVID N, WODARZ, DOMINIK F · 2011 to 2014
$1.5M
NIAID NIH HHS R01 AI078783NIAID NIH HHS R01AI078783NIAID NIH HHS R01 AI093998NIAID NIH HHS R01AI093998
6 · The paper itself

Abstract

Integration is a central event in the replication of retroviruses, yet ≥ 90% of HIV-1 reverse transcripts fail to integrate, resulting in accumulation of unintegrated viral DNA in cells. However, understanding what role, if any, unintegrated viral DNA plays in the natural history of HIV-1 has remained elusive. Unintegrated HIV-1 DNA is reported to possess a limited capacity for gene expression restricted to early gene products and is considered a replicative dead end. Although the majority of peripheral blood CD4(+) T cells are refractory to infection, nonactivated CD4 T cells present in lymphoid and mucosal tissues are major targets for infection. Treatment with cytokine interleukin-2 (IL-2), IL-4, IL-7, or IL-15 renders CD4(+) T cells permissive to HIV-1 infection in the absence of cell activation and proliferation and provides a useful model for infection of resting CD4(+) T cells. We found that infection of cytokine-treated resting CD4(+) T cells in the presence of raltegravir or with integrase active-site mutant HIV-1 yielded de novo virus production following subsequent T cell activation. Infection with integration-competent HIV-1 naturally generated a population of cells generating virus from unintegrated DNA. Latent infection persisted for several weeks and could be activated to virus production by a combination of a histone deacetylase inhibitor and a protein kinase C activator or by T cell activation. HIV-1 Vpr was essential for unintegrated HIV-1 gene expression and de novo virus production in this system. Bypassing integration by this mechanism may allow the preservation of genetic information that otherwise would be lost.

Indexed as

Reverse TranscriptionVirus IntegrationVirus ReplicationCD4-Positive T-LymphocytesDNA, ViralGene Expression Regulation, ViralHIV-1HIV InfectionsHumansViral ProteinsDNA, ViralViral Proteins

Identifiers

PMID24049167
PMCPMC3838139
OpenAlexW2153305651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.